Sym023

DRUG3 trials

Sponsors

Symphogen A/S

Conditions

LymphomaMetastatic CancerSolid Tumor

Phase 1

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

CompletedNCT03311412

Symphogen A/SLymphoma, Metastatic Cancer, Solid Tumor

Start: 2017-11-20End: 2022-03-23Updated: 2023-05-30

Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

CompletedNCT03489343

Symphogen A/SLymphoma, Metastatic Cancer, Solid Tumor

Start: 2018-05-24End: 2020-06-03Updated: 2021-10-12

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

CompletedNCT04641871

Symphogen A/SMetastatic Cancer, Solid Tumor

Start: 2020-10-12End: 2024-06-03Updated: 2024-06-26

Related Papers

Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer.

2026-03-13

Abstract B029: Forging strong bidirectional preclinical and translational research for optimized drug development of Sym023 (S095018), a novel anti-TIM3 antibody

Cancer Immunology Research2025-02-23

Abstract CT133: A phase 1b multicenter study of anti-TIM3 (S095018/Sym023) in combination with anti-PD1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer

Cancer Research2024-04-052 citations

Immune Checkpoints are Important Therapeutic Targets in Cancer Immunotherapy

Cancer Science & Research2021-12-30